180 Therapeutics, a clinical-stage company, was founded by Professor Sir Marc Feldmann, Professor Jagdeep Nanchahal, and Dr Glenn Larsen in 2013.
The discovery of TNF as a mediator of numerous immune-driven diseases originated from analysis of human disease tissue from patients with rheumatoid arthritis, which identified the key mediators of disease.
180 Therapeutics is applying this same approach to the analysis of human disease tissue from patients with active fibrosis or scarring, which again has led to the development of new therapeutic agents and approaches which 180 Therapeutics is developing.
180 Therapeutics’ first major project, is solving an unmet need, treating early -stage fibrosis of the hand, Dupuytren’s contraction. This is being carried out by a local injection of Humira, an anti-TNF antibody.
Frozen shoulder, a common affliction affecting up to 2% of the global population, is due to inflammation and is very painful. Detailed plans have been made for a trial involving the local injection of Humira to frozen shoulders. As this condition is painful, cannabidiol will be also used, propelling 180 Therapeutics to the heart of the second-generation medical marijuana field.
The global treatment market for hand fibrosis is expected to reach $5.5 Billion USD in 2023, rising at a CAGR of 4.4% from 2018.
The market for treating liver fibrosis was worth $12.6B USD in 2018, and is expected to rise to $19.54B USD in 2022 at a CAGR of 11.7%.
25% of the 1.3 million hip fracture patients develop post operative delirium. This accounts for 1.4% of the total health burden in the West.
The condition affects 9% of the population aged 25 to 64, and is more common in diabetics. The only current treatment for the early stage is a local steroid injection.